Clinical trials are expensive to conduct and are very time consuming. The cost of developing a new drug is then reflected in the prices that must be paid by patients and insurers. One aspect of trials that drives up the cost of research is the number of clinical failures. Reducing failures would mean cutting costs, shortening timelines, and getting needed medicines to patients faster. That is where artificial intelligence (AI) and machine learning enter the picture.
Many in the industry believe AI will be a game changer in drug development. Imagine a future where researchers can identify available patients, their location, the best sites and CROs to partner with, and the probability of success of trials before they even begin. That is the promise of AI.
I hope you will enjoy these articles focusing on the benefits and challenges of incorporating AI solutions into clinical studies.